FDA Expands Access to Investigational Drugs, Clarifies Charges

Washington Drug Letter
A A
The FDA has revised its investigational new drug (IND) rules to expand access to such drugs for patients who are seriously ill or have life-threatening conditions and lack other treatment options, and to permit charging for the drugs in studies or expanded-access programs.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00